^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CCR4 receptor antagonist

    Related drugs:
    4d
    Chemokine Networks in Cutaneous T Cell Lymphoma: Tumor Microenvironment Remodeling and Therapeutic Targets. (PubMed, Curr Issues Mol Biol)
    Therapeutically, agents targeting chemokine pathways, most notably the CCR4 monoclonal antibody Mogamulizumab, have demonstrated clinical efficacy, while emerging inhibitors of CCR6, CCR5, and CXCR4 offer promising avenues for intervention. We further highlight how recent single-cell and other high-dimensional omics studies refine cell-type-specific chemokine sources and receptor expression, enabling more precise mapping of chemokine-driven intercellular communication programs in CTCL TME remodeling and better prioritization of therapeutic targets and biomarkers.
    Review • Journal • IO biomarker
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CCR4 (C-C Motif Chemokine Receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD4 (CD4 Molecule) • CCL19 (C-C Motif Chemokine Ligand 19) • CCR7 (Chemokine (C-C motif) receptor 7) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL21 (C-C Motif Chemokine Ligand 21) • CCL22 (C-C Motif Chemokine Ligand 22) • CCL27 (C-C Motif Chemokine Ligand 27) • CCR2 (C-C Motif Chemokine Receptor 2) • CCR8 (C-C Motif Chemokine Receptor 8) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • CCR6 (C-C Motif Chemokine Receptor 6)
    |
    Poteligeo (mogamulizumab-kpkc)
    27d
    Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas (clinicaltrials.gov)
    P2, N=23, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Dec 2026 --> Apr 2027 | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Poteligeo (mogamulizumab-kpkc)
    1m
    FIL_MOGA: Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=100, Completed, Fondazione Italiana Linfomi - ETS | Recruiting --> Completed | N=150 --> 100
    Trial completion • Enrollment change • Real-world evidence
    |
    Poteligeo (mogamulizumab-kpkc)
    1m
    Anti-HER2×CCR4 bispecific antibody enhances antitumor immunity in advanced HER2-positive tumors by chemotaxis blockade and depletion of tumor-associated Tregs, without inducing systemic toxicity. (PubMed, J Immunother Cancer)
    XL-11 mediates potent antitumor immunity in advanced HER2+ tumors while avoiding reducing Tregs throughout the body. XL-11 also acts synergistically with anti-PD-1 therapy, and exhibits favorable stability and PK supporting clinical translation. This work advances Treg-targeted therapies in HER2+ tumors and overcomes the therapeutic limitations of mogamulizumab.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CCR4 (C-C Motif Chemokine Receptor 4)
    |
    HER-2 positive • HER-2 expression • EGFR positive
    |
    Poteligeo (mogamulizumab-kpkc)
    2ms
    Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT) (clinicaltrials.gov)
    P1, N=20, Suspended, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Suspended
    Trial suspension
    |
    CD7 (CD7 Molecule)
    |
    Poteligeo (mogamulizumab-kpkc)
    2ms
    C-C chemokine receptor 4 is a candidate for regulatory T-cell-depletion immunotherapy in differentiated thyroid cancer. (PubMed, Auris Nasus Larynx)
    Tregs were increased and activated in DTC tumor tissue, indicating that they play an important role in creating an immunosuppressive microenvironment in DTC. The results suggest that eTreg-depletion immunotherapy using an anti-CCR4 antibody (mogamulizumab) might be effective for treating DTC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CCR4 (C-C Motif Chemokine Receptor 4) • FOXP3 (Forkhead Box P3)
    |
    Poteligeo (mogamulizumab-kpkc)
    3ms
    scRNA-Seq reveals anti-lymphoma immune responses in mogamulizumab-associated skin eruptions. (PubMed, J Eur Acad Dermatol Venereol)
    Our study provides novel insights into the molecular properties of residual malignant clones within MAR that appear silenced, surrounded by a putatively anti-tumor immune response.
    Journal • IO biomarker
    |
    CCR4 (C-C Motif Chemokine Receptor 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • MMP2 (Matrix metallopeptidase 2) • CCR7 (Chemokine (C-C motif) receptor 7) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • FOXP3 (Forkhead Box P3) • GZMA (Granzyme A) • RUNX3 (RUNX Family Transcription Factor 3)
    |
    Poteligeo (mogamulizumab-kpkc)
    3ms
    Prognostic value of lymphocyte-to-monocyte ratio in relapsed/refractory adult T-cell Leukemia/lymphoma patients receiving mogamulizumab. (PubMed, Clin Immunol)
    LMR is a novel prognostic factor in r/r ATL and may provide useful information when considering mogamulizumab-based treatment.
    Journal • IO biomarker
    |
    CCR4 (C-C Motif Chemokine Receptor 4)
    |
    Poteligeo (mogamulizumab-kpkc)
    3ms
    Repurposing of Chemokine Antagonists for Combined Phase-Resolved Spinal Cord Injury Treatment. (PubMed, Adv Sci (Weinh))
    The effects of mogamulizumab and chemical antagonists of C-C/C-X-C chemokine receptors TAK-799, SB225002, and MK-7123 on SCI recovery in rodents are further estimated. Here blockade of CCR5 and CXCR1/2 chemokine receptors is shown beneficial for amelioration of acute SCI, whereas anti-CCR4 antibody mogamulizumab readily prevents secondary inflammation in the injured area. Summarizing, the current report claims for a novel combined time-resolved therapeutic modality in SCI treatment, which supports feasibility and motivates off-label clinical evaluation in appropriate cohorts.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CCR4 (C-C Motif Chemokine Receptor 4) • IL2 (Interleukin 2) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL22 (C-C Motif Chemokine Ligand 22) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • IL7 (Interleukin 7) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    |
    Poteligeo (mogamulizumab-kpkc) • SB225002 • navarixin (MK-7123)
    4ms
    Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma (clinicaltrials.gov)
    P2, N=34, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Jun 2028 | Trial primary completion date: Jan 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Poteligeo (mogamulizumab-kpkc)
    5ms
    A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy (clinicaltrials.gov)
    P4, N=23, Active, not recruiting, Kyowa Kirin China Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Poteligeo (mogamulizumab-kpkc)
    5ms
    Emerging therapeutic strategies for mature T-cell and natural killer-cell lymphomas. (PubMed, Lancet Haematol)
    Monoclonal antibodies or antibody-drug conjugates targeting T-cell lymphoma surface antigens have been approved, including brentuximab vedotin, for the treatment of CD30-positive nodal and cutaneous T-cell lymphoma, and mogamulizumab, for mycosis fungoides and adult T-cell leukaemia/lymphoma. Novel approaches including cell therapy and adoptive immunotherapy are currently being evaluated. In this Series paper, we discuss the limitations of the conventional treatment options and the use of these novel approaches for mature T-cell and natural killer-cell lymphomas.
    Review • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    Adcetris (brentuximab vedotin) • Poteligeo (mogamulizumab-kpkc)